aluates Reports

$ 0.0

Automative

Global Preeclampsia Therapeutic Market Research Report 2025

Published Date: January 2025

Report Code: QYRE-Auto-20L13581

Global Preeclampsia Therapeutic Market Research Report 2023

BUY CHAPTERS

Global Preeclampsia Therapeutic Market Research Report 2025

Code: QYRE-Auto-20L13581

Report

January 2025

Pages:81

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

LFB

A1M Pharma AB

AMAG Pharmaceuticals

VG Life Sciences, Inc.

PerkinElmer Inc

DRG INSTRUMENTS GMBH

Pluristem Therapeutics Inc

Sera Prognostics,Inc.

Roche Holding AG

Merck& Co. Inc

GlaxoSmithKline PLC

Novartis

Pfizer Inc

Astrazeneca plc

Preeclampsia Therapeutic Market Size

The global market for Preeclampsia Therapeutic was valued at US$ 2510 million in the year 2024 and is projected to reach a revised size of US$ 3492 million by 2031, growing at a CAGR of 4.9% during the forecast period.

Preeclampsia Therapeutic Market

Medications to treat severe preeclampsia usually include: Antihypertensive drugs to lower blood pressure. Anticonvulsant medication, such as magnesium sulfate, to prevent seizures.

The global preeclampsia therapeutic market refers to the market for medications and therapies used in the treatment and management of preeclampsia, a pregnancy-related condition characterized by high blood pressure and damage to organs, most commonly the liver and kidneys. Preeclampsia can pose significant risks to both the mother and the fetus if left untreated.

The market for preeclampsia therapeutics is driven by several factors:

Increasing prevalence of preeclampsia: Preeclampsia is one of the leading causes of maternal and fetal morbidity and mortality worldwide. The increasing prevalence of preeclampsia, particularly in developing countries with limited access to adequate prenatal care, is driving the demand for effective therapeutics.

Rising awareness and diagnosis: There is a growing awareness of the signs and symptoms of preeclampsia, leading to improved diagnosis and timely intervention. Healthcare providers are implementing screening measures and diagnostic guidelines, which contribute to the overall growth of the market.

Advancements in treatment options: The market for preeclampsia therapeutics has witnessed advancements in treatment options, including antihypertensive medications, magnesium sulfate for seizures prophylaxis, and corticosteroids for fetal lung maturation. Ongoing research and development efforts are focused on developing targeted therapies to manage preeclampsia more effectively.

Government initiatives and healthcare policies: Governments across various regions have initiated programs and policies to improve maternal and child health, including the management of preeclampsia. These initiatives aim to enhance access to prenatal care, promote early detection, and provide affordable treatment options, which positively impact the market growth.

Collaborative research and development: Academic institutions, research organizations, and pharmaceutical companies are collaborating to develop novel therapeutic options for preeclampsia. These collaborations facilitate the exchange of knowledge and resources, expediting the development of effective treatment strategies.

Key players in the global preeclampsia therapeutic market include pharmaceutical companies such as Merck & Co., Inc., GlaxoSmithKline Plc, Novartis AG, Pfizer Inc., and AstraZeneca PLC. These companies are actively involved in research, clinical trials, and the development of innovative therapies for preeclampsia.

In conclusion, the global preeclampsia therapeutic market is driven by the increasing prevalence of preeclampsia, rising awareness and diagnosis, advancements in treatment options, government initiatives and healthcare policies, as well as collaborative research and development efforts. As the demand for effective and safe therapeutics for preeclampsia continues to rise, the market is expected to witness significant growth in the coming years.

This report aims to provide a comprehensive presentation of the global market for Preeclampsia Therapeutic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Preeclampsia Therapeutic.

The Preeclampsia Therapeutic market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Preeclampsia Therapeutic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Preeclampsia Therapeutic companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Preeclampsia Therapeutic Market Report

Report Metric	Details
Report Name	Preeclampsia Therapeutic Market
Accounted market size in year	US$ 2510 million
Forecasted market size in 2031	US$ 3492 million
CAGR	4.9%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Antihypertensive Agents Anticonvulsants Antioxidants Others
Segment by Application	Mild Preeclampsia Severe Preeclampsia Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	LFB S.A., A1M Pharma AB, AMAG Pharmaceuticals, VG Life Sciences,Inc., PerkinElmer Inc., Sera Prognostics,Inc., DRG INSTRUMENTS GMBH, Roche Holding AG, Pluristem Therapeutics Inc., Merck & Co., Inc, GlaxoSmithKline Plc, Novartis AG, Pfizer Inc, AstraZeneca PLC
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Preeclampsia Therapeutic company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Preeclampsia Therapeutic Market growing?

Ans: The Preeclampsia Therapeutic Market witnessing a CAGR of 4.9% during the forecast period 2025-2031.

What is the Preeclampsia Therapeutic Market size in 2031?

Ans: The Preeclampsia Therapeutic Market size in 2031 will be US$ 3492 million.

Who are the main players in the Preeclampsia Therapeutic Market report?

Ans: The main players in the Preeclampsia Therapeutic Market are LFB S.A., A1M Pharma AB, AMAG Pharmaceuticals, VG Life Sciences,Inc., PerkinElmer Inc., Sera Prognostics,Inc., DRG INSTRUMENTS GMBH, Roche Holding AG, Pluristem Therapeutics Inc., Merck & Co., Inc, GlaxoSmithKline Plc, Novartis AG, Pfizer Inc, AstraZeneca PLC

What are the Application segmentation covered in the Preeclampsia Therapeutic Market report?

Ans: The Applications covered in the Preeclampsia Therapeutic Market report are Mild Preeclampsia, Severe Preeclampsia, Others

What are the Type segmentation covered in the Preeclampsia Therapeutic Market report?

Ans: The Types covered in the Preeclampsia Therapeutic Market report are Antihypertensive Agents, Anticonvulsants, Antioxidants, Others

Recommended Reports

Maternal & Pregnancy Care

Hypertension & Cardiovascular

Obstetric Drugs & Disorders

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Preeclampsia Therapeutic Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Antihypertensive Agents

1.2.3 Anticonvulsants

1.2.4 Antioxidants

1.2.5 Others

1.3 Market by Application

1.3.1 Global Preeclampsia Therapeutic Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Mild Preeclampsia

1.3.3 Severe Preeclampsia

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Preeclampsia Therapeutic Market Perspective (2020-2031)

2.2 Global Preeclampsia Therapeutic Growth Trends by Region

2.2.1 Global Preeclampsia Therapeutic Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Preeclampsia Therapeutic Historic Market Size by Region (2020-2025)

2.2.3 Preeclampsia Therapeutic Forecasted Market Size by Region (2026-2031)

2.3 Preeclampsia Therapeutic Market Dynamics

2.3.1 Preeclampsia Therapeutic Industry Trends

2.3.2 Preeclampsia Therapeutic Market Drivers

2.3.3 Preeclampsia Therapeutic Market Challenges

2.3.4 Preeclampsia Therapeutic Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Preeclampsia Therapeutic Players by Revenue

3.1.1 Global Top Preeclampsia Therapeutic Players by Revenue (2020-2025)

3.1.2 Global Preeclampsia Therapeutic Revenue Market Share by Players (2020-2025)

3.2 Global Preeclampsia Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Preeclampsia Therapeutic Revenue

3.4 Global Preeclampsia Therapeutic Market Concentration Ratio

3.4.1 Global Preeclampsia Therapeutic Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Preeclampsia Therapeutic Revenue in 2024

3.5 Global Key Players of Preeclampsia Therapeutic Head office and Area Served

3.6 Global Key Players of Preeclampsia Therapeutic, Product and Application

3.7 Global Key Players of Preeclampsia Therapeutic, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Preeclampsia Therapeutic Breakdown Data by Type

4.1 Global Preeclampsia Therapeutic Historic Market Size by Type (2020-2025)

4.2 Global Preeclampsia Therapeutic Forecasted Market Size by Type (2026-2031)

5 Preeclampsia Therapeutic Breakdown Data by Application

5.1 Global Preeclampsia Therapeutic Historic Market Size by Application (2020-2025)

5.2 Global Preeclampsia Therapeutic Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Preeclampsia Therapeutic Market Size (2020-2031)

6.2 North America Preeclampsia Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Preeclampsia Therapeutic Market Size by Country (2020-2025)

6.4 North America Preeclampsia Therapeutic Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Preeclampsia Therapeutic Market Size (2020-2031)

7.2 Europe Preeclampsia Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Preeclampsia Therapeutic Market Size by Country (2020-2025)

7.4 Europe Preeclampsia Therapeutic Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Preeclampsia Therapeutic Market Size (2020-2031)

8.2 Asia-Pacific Preeclampsia Therapeutic Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Preeclampsia Therapeutic Market Size by Region (2020-2025)

8.4 Asia-Pacific Preeclampsia Therapeutic Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Preeclampsia Therapeutic Market Size (2020-2031)

9.2 Latin America Preeclampsia Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Preeclampsia Therapeutic Market Size by Country (2020-2025)

9.4 Latin America Preeclampsia Therapeutic Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Preeclampsia Therapeutic Market Size (2020-2031)

10.2 Middle East & Africa Preeclampsia Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Preeclampsia Therapeutic Market Size by Country (2020-2025)

10.4 Middle East & Africa Preeclampsia Therapeutic Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 LFB S.A.

11.1.1 LFB S.A. Company Details

11.1.2 LFB S.A. Business Overview

11.1.3 LFB S.A. Preeclampsia Therapeutic Introduction

11.1.4 LFB S.A. Revenue in Preeclampsia Therapeutic Business (2020-2025)

11.1.5 LFB S.A. Recent Development

11.2 A1M Pharma AB

11.2.1 A1M Pharma AB Company Details

11.2.2 A1M Pharma AB Business Overview

11.2.3 A1M Pharma AB Preeclampsia Therapeutic Introduction

11.2.4 A1M Pharma AB Revenue in Preeclampsia Therapeutic Business (2020-2025)

11.2.5 A1M Pharma AB Recent Development

11.3 AMAG Pharmaceuticals

11.3.1 AMAG Pharmaceuticals Company Details

11.3.2 AMAG Pharmaceuticals Business Overview

11.3.3 AMAG Pharmaceuticals Preeclampsia Therapeutic Introduction

11.3.4 AMAG Pharmaceuticals Revenue in Preeclampsia Therapeutic Business (2020-2025)

11.3.5 AMAG Pharmaceuticals Recent Development

11.4 VG Life Sciences,Inc.

11.4.1 VG Life Sciences,Inc. Company Details

11.4.2 VG Life Sciences,Inc. Business Overview

11.4.3 VG Life Sciences,Inc. Preeclampsia Therapeutic Introduction

11.4.4 VG Life Sciences,Inc. Revenue in Preeclampsia Therapeutic Business (2020-2025)

11.4.5 VG Life Sciences,Inc. Recent Development

11.5 PerkinElmer Inc.

11.5.1 PerkinElmer Inc. Company Details

11.5.2 PerkinElmer Inc. Business Overview

11.5.3 PerkinElmer Inc. Preeclampsia Therapeutic Introduction

11.5.4 PerkinElmer Inc. Revenue in Preeclampsia Therapeutic Business (2020-2025)

11.5.5 PerkinElmer Inc. Recent Development

11.6 Sera Prognostics,Inc.

11.6.1 Sera Prognostics,Inc. Company Details

11.6.2 Sera Prognostics,Inc. Business Overview

11.6.3 Sera Prognostics,Inc. Preeclampsia Therapeutic Introduction

11.6.4 Sera Prognostics,Inc. Revenue in Preeclampsia Therapeutic Business (2020-2025)

11.6.5 Sera Prognostics,Inc. Recent Development

11.7 DRG INSTRUMENTS GMBH

11.7.1 DRG INSTRUMENTS GMBH Company Details

11.7.2 DRG INSTRUMENTS GMBH Business Overview

11.7.3 DRG INSTRUMENTS GMBH Preeclampsia Therapeutic Introduction

11.7.4 DRG INSTRUMENTS GMBH Revenue in Preeclampsia Therapeutic Business (2020-2025)

11.7.5 DRG INSTRUMENTS GMBH Recent Development

11.8 Roche Holding AG

11.8.1 Roche Holding AG Company Details

11.8.2 Roche Holding AG Business Overview

11.8.3 Roche Holding AG Preeclampsia Therapeutic Introduction

11.8.4 Roche Holding AG Revenue in Preeclampsia Therapeutic Business (2020-2025)

11.8.5 Roche Holding AG Recent Development

11.9 Pluristem Therapeutics Inc.

11.9.1 Pluristem Therapeutics Inc. Company Details

11.9.2 Pluristem Therapeutics Inc. Business Overview

11.9.3 Pluristem Therapeutics Inc. Preeclampsia Therapeutic Introduction

11.9.4 Pluristem Therapeutics Inc. Revenue in Preeclampsia Therapeutic Business (2020-2025)

11.9.5 Pluristem Therapeutics Inc. Recent Development

11.10 Merck & Co., Inc

11.10.1 Merck & Co., Inc Company Details

11.10.2 Merck & Co., Inc Business Overview

11.10.3 Merck & Co., Inc Preeclampsia Therapeutic Introduction

11.10.4 Merck & Co., Inc Revenue in Preeclampsia Therapeutic Business (2020-2025)

11.10.5 Merck & Co., Inc Recent Development

11.11 GlaxoSmithKline Plc

11.11.1 GlaxoSmithKline Plc Company Details

11.11.2 GlaxoSmithKline Plc Business Overview

11.11.3 GlaxoSmithKline Plc Preeclampsia Therapeutic Introduction

11.11.4 GlaxoSmithKline Plc Revenue in Preeclampsia Therapeutic Business (2020-2025)

11.11.5 GlaxoSmithKline Plc Recent Development

11.12 Novartis AG

11.12.1 Novartis AG Company Details

11.12.2 Novartis AG Business Overview

11.12.3 Novartis AG Preeclampsia Therapeutic Introduction

11.12.4 Novartis AG Revenue in Preeclampsia Therapeutic Business (2020-2025)

11.12.5 Novartis AG Recent Development

11.13 Pfizer Inc

11.13.1 Pfizer Inc Company Details

11.13.2 Pfizer Inc Business Overview

11.13.3 Pfizer Inc Preeclampsia Therapeutic Introduction

11.13.4 Pfizer Inc Revenue in Preeclampsia Therapeutic Business (2020-2025)

11.13.5 Pfizer Inc Recent Development

11.14 AstraZeneca PLC

11.14.1 AstraZeneca PLC Company Details

11.14.2 AstraZeneca PLC Business Overview

11.14.3 AstraZeneca PLC Preeclampsia Therapeutic Introduction

11.14.4 AstraZeneca PLC Revenue in Preeclampsia Therapeutic Business (2020-2025)

11.14.5 AstraZeneca PLC Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

LFB

A1M Pharma AB

AMAG Pharmaceuticals

VG Life Sciences, Inc.

PerkinElmer Inc

DRG INSTRUMENTS GMBH

Pluristem Therapeutics Inc

Sera Prognostics,Inc.

Roche Holding AG

Merck& Co. Inc

GlaxoSmithKline PLC

Novartis

Pfizer Inc

Astrazeneca plc

List of Tables

Table 1. Global Preeclampsia Therapeutic Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Antihypertensive Agents

Table 3. Key Players of Anticonvulsants

Table 4. Key Players of Antioxidants

Table 5. Key Players of Others

Table 6. Global Preeclampsia Therapeutic Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Preeclampsia Therapeutic Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Preeclampsia Therapeutic Market Size by Region (2020-2025) & (US$ Million)

Table 9. Global Preeclampsia Therapeutic Market Share by Region (2020-2025)

Table 10. Global Preeclampsia Therapeutic Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 11. Global Preeclampsia Therapeutic Market Share by Region (2026-2031)

Table 12. Preeclampsia Therapeutic Market Trends

Table 13. Preeclampsia Therapeutic Market Drivers

Table 14. Preeclampsia Therapeutic Market Challenges

Table 15. Preeclampsia Therapeutic Market Restraints

Table 16. Global Preeclampsia Therapeutic Revenue by Players (2020-2025) & (US$ Million)

Table 17. Global Preeclampsia Therapeutic Market Share by Players (2020-2025)

Table 18. Global Top Preeclampsia Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Preeclampsia Therapeutic as of 2024)

Table 19. Ranking of Global Top Preeclampsia Therapeutic Companies by Revenue (US$ Million) in 2024

Table 20. Global 5 Largest Players Market Share by Preeclampsia Therapeutic Revenue (CR5 and HHI) & (2020-2025)

Table 21. Global Key Players of Preeclampsia Therapeutic, Headquarters and Area Served

Table 22. Global Key Players of Preeclampsia Therapeutic, Product and Application

Table 23. Global Key Players of Preeclampsia Therapeutic, Date of Enter into This Industry

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Preeclampsia Therapeutic Market Size by Type (2020-2025) & (US$ Million)

Table 26. Global Preeclampsia Therapeutic Revenue Market Share by Type (2020-2025)

Table 27. Global Preeclampsia Therapeutic Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 28. Global Preeclampsia Therapeutic Revenue Market Share by Type (2026-2031)

Table 29. Global Preeclampsia Therapeutic Market Size by Application (2020-2025) & (US$ Million)

Table 30. Global Preeclampsia Therapeutic Revenue Market Share by Application (2020-2025)

Table 31. Global Preeclampsia Therapeutic Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 32. Global Preeclampsia Therapeutic Revenue Market Share by Application (2026-2031)

Table 33. North America Preeclampsia Therapeutic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 34. North America Preeclampsia Therapeutic Market Size by Country (2020-2025) & (US$ Million)

Table 35. North America Preeclampsia Therapeutic Market Size by Country (2026-2031) & (US$ Million)

Table 36. Europe Preeclampsia Therapeutic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. Europe Preeclampsia Therapeutic Market Size by Country (2020-2025) & (US$ Million)

Table 38. Europe Preeclampsia Therapeutic Market Size by Country (2026-2031) & (US$ Million)

Table 39. Asia-Pacific Preeclampsia Therapeutic Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 40. Asia-Pacific Preeclampsia Therapeutic Market Size by Region (2020-2025) & (US$ Million)

Table 41. Asia-Pacific Preeclampsia Therapeutic Market Size by Region (2026-2031) & (US$ Million)

Table 42. Latin America Preeclampsia Therapeutic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 43. Latin America Preeclampsia Therapeutic Market Size by Country (2020-2025) & (US$ Million)

Table 44. Latin America Preeclampsia Therapeutic Market Size by Country (2026-2031) & (US$ Million)

Table 45. Middle East & Africa Preeclampsia Therapeutic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Middle East & Africa Preeclampsia Therapeutic Market Size by Country (2020-2025) & (US$ Million)

Table 47. Middle East & Africa Preeclampsia Therapeutic Market Size by Country (2026-2031) & (US$ Million)

Table 48. LFB S.A. Company Details

Table 49. LFB S.A. Business Overview

Table 50. LFB S.A. Preeclampsia Therapeutic Product

Table 51. LFB S.A. Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)

Table 52. LFB S.A. Recent Development

Table 53. A1M Pharma AB Company Details

Table 54. A1M Pharma AB Business Overview

Table 55. A1M Pharma AB Preeclampsia Therapeutic Product

Table 56. A1M Pharma AB Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)

Table 57. A1M Pharma AB Recent Development

Table 58. AMAG Pharmaceuticals Company Details

Table 59. AMAG Pharmaceuticals Business Overview

Table 60. AMAG Pharmaceuticals Preeclampsia Therapeutic Product

Table 61. AMAG Pharmaceuticals Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)

Table 62. AMAG Pharmaceuticals Recent Development

Table 63. VG Life Sciences,Inc. Company Details

Table 64. VG Life Sciences,Inc. Business Overview

Table 65. VG Life Sciences,Inc. Preeclampsia Therapeutic Product

Table 66. VG Life Sciences,Inc. Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)

Table 67. VG Life Sciences,Inc. Recent Development

Table 68. PerkinElmer Inc. Company Details

Table 69. PerkinElmer Inc. Business Overview

Table 70. PerkinElmer Inc. Preeclampsia Therapeutic Product

Table 71. PerkinElmer Inc. Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)

Table 72. PerkinElmer Inc. Recent Development

Table 73. Sera Prognostics,Inc. Company Details

Table 74. Sera Prognostics,Inc. Business Overview

Table 75. Sera Prognostics,Inc. Preeclampsia Therapeutic Product

Table 76. Sera Prognostics,Inc. Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)

Table 77. Sera Prognostics,Inc. Recent Development

Table 78. DRG INSTRUMENTS GMBH Company Details

Table 79. DRG INSTRUMENTS GMBH Business Overview

Table 80. DRG INSTRUMENTS GMBH Preeclampsia Therapeutic Product

Table 81. DRG INSTRUMENTS GMBH Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)

Table 82. DRG INSTRUMENTS GMBH Recent Development

Table 83. Roche Holding AG Company Details

Table 84. Roche Holding AG Business Overview

Table 85. Roche Holding AG Preeclampsia Therapeutic Product

Table 86. Roche Holding AG Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)

Table 87. Roche Holding AG Recent Development

Table 88. Pluristem Therapeutics Inc. Company Details

Table 89. Pluristem Therapeutics Inc. Business Overview

Table 90. Pluristem Therapeutics Inc. Preeclampsia Therapeutic Product

Table 91. Pluristem Therapeutics Inc. Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)

Table 92. Pluristem Therapeutics Inc. Recent Development

Table 93. Merck & Co., Inc Company Details

Table 94. Merck & Co., Inc Business Overview

Table 95. Merck & Co., Inc Preeclampsia Therapeutic Product

Table 96. Merck & Co., Inc Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)

Table 97. Merck & Co., Inc Recent Development

Table 98. GlaxoSmithKline Plc Company Details

Table 99. GlaxoSmithKline Plc Business Overview

Table 100. GlaxoSmithKline Plc Preeclampsia Therapeutic Product

Table 101. GlaxoSmithKline Plc Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)

Table 102. GlaxoSmithKline Plc Recent Development

Table 103. Novartis AG Company Details

Table 104. Novartis AG Business Overview

Table 105. Novartis AG Preeclampsia Therapeutic Product

Table 106. Novartis AG Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)

Table 107. Novartis AG Recent Development

Table 108. Pfizer Inc Company Details

Table 109. Pfizer Inc Business Overview

Table 110. Pfizer Inc Preeclampsia Therapeutic Product

Table 111. Pfizer Inc Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)

Table 112. Pfizer Inc Recent Development

Table 113. AstraZeneca PLC Company Details

Table 114. AstraZeneca PLC Business Overview

Table 115. AstraZeneca PLC Preeclampsia Therapeutic Product

Table 116. AstraZeneca PLC Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)

Table 117. AstraZeneca PLC Recent Development

Table 118. Research Programs/Design for This Report

Table 119. Key Data Information from Secondary Sources

Table 120. Key Data Information from Primary Sources

Table 121. Authors List of This Report

List of Figures

Figure 1. Preeclampsia Therapeutic Picture

Figure 2. Global Preeclampsia Therapeutic Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Preeclampsia Therapeutic Market Share by Type: 2024 VS 2031

Figure 4. Antihypertensive Agents Features

Figure 5. Anticonvulsants Features

Figure 6. Antioxidants Features

Figure 7. Others Features

Figure 8. Global Preeclampsia Therapeutic Market Size by Application (2020-2031) & (US$ Million)

Figure 9. Global Preeclampsia Therapeutic Market Share by Application: 2024 VS 2031

Figure 10. Mild Preeclampsia Case Studies

Figure 11. Severe Preeclampsia Case Studies

Figure 12. Others Case Studies

Figure 13. Preeclampsia Therapeutic Report Years Considered

Figure 14. Global Preeclampsia Therapeutic Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 15. Global Preeclampsia Therapeutic Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 16. Global Preeclampsia Therapeutic Market Share by Region: 2024 VS 2031

Figure 17. Global Preeclampsia Therapeutic Market Share by Players in 2024

Figure 18. Global Top Preeclampsia Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Preeclampsia Therapeutic as of 2024)

Figure 19. The Top 10 and 5 Players Market Share by Preeclampsia Therapeutic Revenue in 2024

Figure 20. North America Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. North America Preeclampsia Therapeutic Market Share by Country (2020-2031)

Figure 22. United States Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Canada Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Preeclampsia Therapeutic Market Share by Country (2020-2031)

Figure 26. Germany Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. France Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. U.K. Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Italy Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Russia Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Nordic Countries Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific Preeclampsia Therapeutic Market Share by Region (2020-2031)

Figure 34. China Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Japan Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. South Korea Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Southeast Asia Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. India Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Australia Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America Preeclampsia Therapeutic Market Share by Country (2020-2031)

Figure 42. Mexico Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Brazil Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa Preeclampsia Therapeutic Market Share by Country (2020-2031)

Figure 46. Turkey Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Saudi Arabia Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. UAE Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. LFB S.A. Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)

Figure 50. A1M Pharma AB Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)

Figure 51. AMAG Pharmaceuticals Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)

Figure 52. VG Life Sciences,Inc. Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)

Figure 53. PerkinElmer Inc. Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)

Figure 54. Sera Prognostics,Inc. Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)

Figure 55. DRG INSTRUMENTS GMBH Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)

Figure 56. Roche Holding AG Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)

Figure 57. Pluristem Therapeutics Inc. Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)

Figure 58. Merck & Co., Inc Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)

Figure 59. GlaxoSmithKline Plc Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)

Figure 60. Novartis AG Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)

Figure 61. Pfizer Inc Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)

Figure 62. AstraZeneca PLC Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)

Figure 63. Bottom-up and Top-down Approaches for This Report

Figure 64. Data Triangulation

Figure 65. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Magnesium Sulfate Injection Market Research Report 2024

Global Pre Eclampsia Treatment Market Research Report 2025

Valsartan Hydrochlorothiazide Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Fosinopril Sodium Tablets Market Research Report 2024

Global Hypertension and Heart Failure Drugs Market Insights Forecast to 2030

Global Pregnancy Medication Market Research Report 2025

Global Valsartan Tablets Market Research Report 2024

Global Telmisartan Tablet Market Research Report 2024

Preeclampsia Diagnostics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Preeclampsia Laboratory Testing Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Antihypertensive Drugs Market Research Report 2024

Hypertension Medications Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Blood Pressure Medications Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Drugs for Conn s Syndrome Market Research Report 2024

Preterm Birth Prevention and Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Irbesartan Tablets Market Insights Forecast to 2030

Hypertension Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Intraocular Antihypertensive Market Research Report 2025

Global Epoprostenol Sodium Drugs Market Insights Forecast to 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions